JP6576249B2 - 癌におけるクロマチン転写促進因子（ｆａｃｔ）の使用 - Google Patents

癌におけるクロマチン転写促進因子（ｆａｃｔ）の使用 Download PDF

Info

Publication number
JP6576249B2
JP6576249B2 JP2015557203A JP2015557203A JP6576249B2 JP 6576249 B2 JP6576249 B2 JP 6576249B2 JP 2015557203 A JP2015557203 A JP 2015557203A JP 2015557203 A JP2015557203 A JP 2015557203A JP 6576249 B2 JP6576249 B2 JP 6576249B2
Authority
JP
Japan
Prior art keywords
tumor
cells
fact
cancer
ssrp1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015557203A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016514248A (ja
JP2016514248A5 (enExample
Inventor
カテリーナ グロワ，
カテリーナ グロワ，
Original Assignee
インクロン， インコーポレイテッド
インクロン， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インクロン， インコーポレイテッド, インクロン， インコーポレイテッド filed Critical インクロン， インコーポレイテッド
Publication of JP2016514248A publication Critical patent/JP2016514248A/ja
Publication of JP2016514248A5 publication Critical patent/JP2016514248A5/ja
Application granted granted Critical
Publication of JP6576249B2 publication Critical patent/JP6576249B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2015557203A 2013-02-11 2014-02-11 癌におけるクロマチン転写促進因子（ｆａｃｔ）の使用 Expired - Fee Related JP6576249B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361763266P 2013-02-11 2013-02-11
US61/763,266 2013-02-11
US201361883802P 2013-09-27 2013-09-27
US61/883,802 2013-09-27
PCT/US2014/015854 WO2014124454A1 (en) 2013-02-11 2014-02-11 Use of facilitates chromatin transcription complex (fact) in cancer

Publications (3)

Publication Number Publication Date
JP2016514248A JP2016514248A (ja) 2016-05-19
JP2016514248A5 JP2016514248A5 (enExample) 2017-03-16
JP6576249B2 true JP6576249B2 (ja) 2019-09-18

Family

ID=51300203

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015557203A Expired - Fee Related JP6576249B2 (ja) 2013-02-11 2014-02-11 癌におけるクロマチン転写促進因子（ｆａｃｔ）の使用

Country Status (6)

Country Link
US (1) US10386370B2 (enExample)
EP (1) EP2954331B1 (enExample)
JP (1) JP6576249B2 (enExample)
CN (1) CN104981697B (enExample)
EA (1) EA036615B1 (enExample)
WO (1) WO2014124454A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108333366B (zh) * 2018-01-26 2020-06-12 南通大学附属医院 一种实验性监测肝细胞恶性转化过程大鼠模型的建立方法
CN109136376B (zh) * 2018-05-21 2021-09-21 中国医科大学附属第四医院 一种膀胱癌相关环状RNA的应用和siRNA及其用途
CN113721020B (zh) * 2021-09-14 2022-06-24 大连医科大学附属第二医院 Ctsf在非小细胞肺癌诊断中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2715680A1 (de) 1977-04-07 1978-10-12 Henkel Kgaa Haarfaerbemittel
US7081340B2 (en) 2002-03-13 2006-07-25 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
AU2003272175A1 (en) 2002-10-21 2004-05-04 Aprea Ab Reactivation of wild type p53 in human tumour cells by a low molecular weight compound
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
CA3061769C (en) 2003-06-24 2021-10-26 Genomic Health, Inc. Methods of predicting the likelihood of long-term survival of a human patient with node-negative, estrogen receptor (er) positive, invasive ductal breast cancer without the recurrence of breast cancer
ES2905579T3 (es) 2003-07-10 2022-04-11 Genomic Health Inc Algoritmo del perfil de expresión y prueba para el pronóstico de la recaída del cáncer de mama
US7169802B2 (en) 2003-12-23 2007-01-30 Cephalon, Inc. Fused pyrrolocarbazoles
US20100047783A1 (en) 2006-06-20 2010-02-25 El-Diery Wafik S Small molecule modulators of p53 family signaling
WO2009055823A2 (en) 2007-10-26 2009-04-30 Progen Pharmaceuticals Limited Method to predict responsiveness of breast cancer to polyaminetype chemotherapy
AU2009246009A1 (en) 2008-05-14 2009-11-19 University Health Network Prognostic and predictive gene signature for non-small cell lung cancer and adjuvant chemotherapy
GEP20156300B (en) 2008-05-20 2015-06-25 Incuron Llc Inducing cell death by inhibiting adaptive heat shock response
US20100081666A1 (en) 2008-07-14 2010-04-01 Wyeth Src activation for determining cancer prognosis and as a target for cancer therapy
UA107652C2 (en) 2008-10-06 2015-02-10 Incuron Llc Carbazole compounds and therapeutic uses of the compounds
US20100331210A1 (en) 2009-05-29 2010-12-30 Precision Therapeutics, Inc. Methods and systems for evaluating the sensitivity or resistance of tumor specimens to chemotherapeutic agents
EP2830616A1 (en) 2012-03-27 2015-02-04 Incuron LLC Curaxins for use in treating breast cancer and method for identifying patients likely to respond
US20140066465A1 (en) 2012-09-04 2014-03-06 The Cleveland Clinic Foundation CANCER TREATMENT USING TYROSINE KINASE AND NF-kB INHIBITORS

Also Published As

Publication number Publication date
EP2954331A1 (en) 2015-12-16
CN104981697A (zh) 2015-10-14
EP2954331B1 (en) 2018-03-28
WO2014124454A1 (en) 2014-08-14
US20160033515A1 (en) 2016-02-04
US10386370B2 (en) 2019-08-20
HK1218953A1 (en) 2017-03-17
EA201591304A1 (ru) 2016-01-29
EA036615B1 (ru) 2020-11-30
CN104981697B (zh) 2017-08-04
JP2016514248A (ja) 2016-05-19
EP2954331A4 (en) 2016-08-31

Similar Documents

Publication Publication Date Title
US11421233B2 (en) Methods relating to circulating tumor cell clusters and the treatment of cancer
JP6900314B2 (ja) 膀胱癌の治療、診断、及び予後判定方法
Chu et al. Heterogeneity in NECTIN4 expression across molecular subtypes of urothelial cancer mediates sensitivity to enfortumab vedotin
Cristofanilli Circulating tumor cells, disease progression, and survival in metastatic breast cancer
Li et al. ALK-rearranged lung cancer in Chinese: a comprehensive assessment of clinicopathology, IHC, FISH and RT-PCR
Viola et al. A validation study for the use of ROS1 immunohistochemical staining in screening for ROS1 translocations in lung cancer
EP1926996A1 (en) Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2013052480A1 (en) Marker-based prognostic risk score in colon cancer
CN101815793A (zh) 诊断和治疗癌症的方法
Jung et al. Update on C-cell neuroendocrine neoplasm: prognostic and predictive histopathologic and molecular features of medullary thyroid carcinoma
JP6657103B2 (ja) ステージｉｉの結腸直腸がんにおける予測マーカーとしてのｇアルファ相互作用小胞結合タンパク質（ｇｉｖ）
CN115997123A (zh) 用于预测实体癌患者在术前辅助治疗后复发和/或死亡风险的方法
Baldia et al. Fibroblast growth factor receptor (FGFR) alterations in squamous differentiated bladder cancer: a putative therapeutic target for a small subgroup
WO2011047019A1 (en) An objective, quantitative method to predict histological subtype in non-small cell lung cancer
CN104981697B (zh) 促染色质转录复合物(fact)在癌症中的用途
JP2015527341A (ja) 抗ｅｇｆｒ薬物による処置のための非小細胞肺癌患者を同定するための組織学的マーカー
JP2021508835A (ja) 腫瘍細胞中のＲＡＤ５１ ｆｏｃｉの検出に基づく方法
US8609354B2 (en) Method for selecting patients for treatment with an EGFR inhibitor
HK1218953B (en) Use of facilitates chromatin transcription complex (fact) in cancer
Chislock et al. DTC-Flow: a flow cytometry-based detection platform for characterizing bone marrow disseminated tumor cells in breast cancer
Ozcan et al. Fibroblast growth factor receptor 1 gene (FGFR1) expression in serous ovarian tumors
Scerri Herceptin® resistance in breast cancer: a pathwaybased approach
Watson Molecular profiling of clinical drug resistance
Esteva et al. Serum Tumor Markers and Circulating Tumor Cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170209

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20171108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180412

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181002

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190327

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20190516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190516

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190816

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190820

R150 Certificate of patent or registration of utility model

Ref document number: 6576249

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees